Market Closed -
BME
11:35:27 2024-05-07 am EDT
|
5-day change
|
1st Jan Change
|
3.5
EUR
|
+0.43%
|
|
+2.79%
|
+10.76%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,370
|
980.4
|
1,019
|
1,074
|
992.3
|
1,089
|
-
|
-
|
Enterprise Value (EV)
1 |
1,324
|
905.1
|
969.7
|
1,045
|
992.3
|
1,099
|
1,025
|
1,042
|
P/E ratio
|
21.4
x
|
14
x
|
12.9
x
|
12
x
|
-
|
12.1
x
|
11.8
x
|
12.4
x
|
Yield
|
3.36%
|
4.87%
|
5.75%
|
4.42%
|
-
|
4.43%
|
4.5%
|
2.67%
|
Capitalization / Revenue
|
3.57
x
|
2.38
x
|
2.56
x
|
2.45
x
|
2.2
x
|
2.29
x
|
2.19
x
|
2.18
x
|
EV / Revenue
|
3.46
x
|
2.2
x
|
2.43
x
|
2.38
x
|
2.2
x
|
2.31
x
|
2.06
x
|
2.09
x
|
EV / EBITDA
|
14.5
x
|
8.45
x
|
8.48
x
|
8.65
x
|
8.12
x
|
8.68
x
|
7.73
x
|
8.24
x
|
EV / FCF
|
26.2
x
|
17.2
x
|
47.9
x
|
241
x
|
-
|
20.1
x
|
12.9
x
|
11
x
|
FCF Yield
|
3.82%
|
5.83%
|
2.09%
|
0.42%
|
-
|
4.96%
|
7.73%
|
9.05%
|
Price to Book
|
-
|
-
|
1.9
x
|
1.79
x
|
-
|
1.56
x
|
1.46
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
273,938
|
280,909
|
292,875
|
305,996
|
314,021
|
311,249
|
-
|
-
|
Reference price
2 |
5.000
|
3.490
|
3.478
|
3.510
|
3.160
|
3.500
|
3.500
|
3.500
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/25/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
383.2
|
411.5
|
398.6
|
438.8
|
451.2
|
476.3
|
496.5
|
499.3
|
EBITDA
1 |
91.51
|
107.1
|
114.4
|
120.8
|
122.2
|
126.7
|
132.5
|
126.4
|
EBIT
1 |
74.86
|
86.77
|
94.28
|
101.5
|
102.8
|
106.5
|
110.8
|
104
|
Operating Margin
|
19.54%
|
21.09%
|
23.65%
|
23.13%
|
22.79%
|
22.36%
|
22.31%
|
20.83%
|
Earnings before Tax (EBT)
1 |
74.18
|
84.88
|
93.99
|
101.4
|
102.9
|
109
|
114
|
113
|
Net income
1 |
63.96
|
72.55
|
83.16
|
89.55
|
91.9
|
89.67
|
92
|
89
|
Net margin
|
16.69%
|
17.63%
|
20.86%
|
20.41%
|
20.37%
|
18.82%
|
18.53%
|
17.82%
|
EPS
2 |
0.2340
|
0.2500
|
0.2700
|
0.2930
|
-
|
0.2900
|
0.2967
|
0.2833
|
Free Cash Flow
1 |
50.61
|
52.77
|
20.23
|
4.34
|
-
|
54.55
|
79.25
|
94.35
|
FCF margin
|
13.21%
|
12.82%
|
5.08%
|
0.99%
|
-
|
11.45%
|
15.96%
|
18.9%
|
FCF Conversion (EBITDA)
|
55.31%
|
49.25%
|
17.69%
|
3.59%
|
-
|
43.05%
|
59.8%
|
74.62%
|
FCF Conversion (Net income)
|
79.13%
|
72.73%
|
24.33%
|
4.85%
|
-
|
60.84%
|
86.14%
|
106.01%
|
Dividend per Share
2 |
0.1680
|
0.1700
|
0.2000
|
0.1550
|
-
|
0.1550
|
0.1575
|
0.0933
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/25/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2024 Q1
|
---|
Net sales
|
201.3
|
192.2
|
128.7
|
77.68
|
116.2
|
114.8
|
231
|
121
|
118.4
|
117.8
|
-
|
125.8
|
-
|
EBITDA
1 |
66.99
|
63.12
|
31.95
|
19.29
|
35.92
|
35.04
|
70.95
|
29.68
|
37
|
34.25
|
71.41
|
-
|
40
|
EBIT
1 |
55.86
|
55.27
|
27.96
|
11.04
|
-
|
30.26
|
61.86
|
24.39
|
32.55
|
29.39
|
61.94
|
25.47
|
35
|
Operating Margin
|
27.75%
|
28.76%
|
21.74%
|
14.21%
|
-
|
26.36%
|
26.78%
|
20.15%
|
27.48%
|
24.96%
|
-
|
20.25%
|
-
|
Earnings before Tax (EBT)
|
55.09
|
-
|
27.93
|
-
|
31.79
|
30.44
|
62.23
|
24.2
|
32.58
|
29.65
|
62.23
|
25.37
|
-
|
Net income
1 |
45.58
|
47.19
|
23.96
|
12
|
26.62
|
26.44
|
53.06
|
20.94
|
27.62
|
25.38
|
53
|
21.16
|
28
|
Net margin
|
22.64%
|
24.55%
|
18.63%
|
15.45%
|
22.91%
|
23.03%
|
22.97%
|
17.3%
|
23.31%
|
21.56%
|
-
|
16.82%
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/29/20
|
7/28/21
|
10/29/21
|
2/25/22
|
4/29/22
|
7/28/22
|
7/28/22
|
10/27/22
|
5/2/23
|
7/28/23
|
7/28/23
|
10/25/23
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
9.8
|
-
|
-
|
Net Cash position
1 |
45.4
|
75.2
|
48.9
|
29.4
|
-
|
-
|
64.5
|
47.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
0.0773
x
|
-
|
-
|
Free Cash Flow
1 |
50.6
|
52.8
|
20.2
|
4.34
|
-
|
54.6
|
79.3
|
94.4
|
ROE (net income / shareholders' equity)
|
16.6%
|
16.4%
|
16.5%
|
15.7%
|
-
|
13%
|
12.5%
|
11.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
13.1%
|
-
|
10.6%
|
10.4%
|
9.8%
|
Assets
1 |
-
|
-
|
-
|
683.7
|
-
|
845.9
|
884.6
|
908.2
|
Book Value Per Share
2 |
-
|
-
|
1.830
|
1.960
|
-
|
2.250
|
2.400
|
2.540
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
21.4
|
25.7
|
59.4
|
102
|
-
|
43.9
|
27
|
23
|
Capex / Sales
|
5.59%
|
6.25%
|
14.91%
|
23.35%
|
-
|
9.22%
|
5.44%
|
4.61%
|
Announcement Date
|
2/28/20
|
2/26/21
|
2/25/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Average target price
3.708
EUR Spread / Average Target +5.93% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.76% | 1.17B | | +33.43% | 690B | | +26.43% | 546B | | -5.12% | 358B | | +19.59% | 323B | | +4.89% | 287B | | +14.32% | 235B | | +5.79% | 199B | | -9.49% | 195B | | +4.26% | 161B |
Other Pharmaceuticals
|